$738.00
At close: Nov 22, 4:00 PM EDT
$738.00
00.00%
After Hours: Nov 22, 4:00 PM EDT
Comments
Loading...
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock, Earnings Estimates, EPS, And Revenue
Regeneron Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Jan 31
EPS Estimate
$11.790
Quarterly Revenue Estimate
$3.8B
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$13.8B
Analyze the earnings history of Regeneron Pharmaceuticals using advanced sorting and filters.
Data brought to you by Benzinga APIs
Regeneron Pharmaceuticals (REGN) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-10-31 | $12.46 | $11.69 | 6.59 % |
| Jun 2024 | 2024-08-01 | $11.56 | $10.53 | 9.78 % |
| Mar 2024 | 2024-05-02 | $9.55 | $10.10 | -5.45 % |
| Dec 2023 | 2024-02-02 | $11.86 | $10.77 | 10.1 % |
Regeneron Pharmaceuticals (REGN) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-10-31 | $3.72B | $3.67B | 1.39 % |
| Jun 2024 | 2024-08-01 | $3.55B | $3.36B | 5.57 % |
| Mar 2024 | 2024-05-02 | $3.15B | $3.22B | -2.33 % |
| Dec 2023 | 2024-02-02 | $3.43B | $3.29B | 4.38 % |
FAQ
When is Regeneron Pharmaceuticals (NASDAQ:REGN) reporting earnings?
Regeneron Pharmaceuticals (REGN) is scheduled to report earnings on January 31, 2025. The last reported earnings were for reported on October 31, 2024 for Q3.
What were the latest earnings per share (EPS) for Regeneron Pharmaceuticals (NASDAQ:REGN)?
The Actual EPS was $12.46, which beat the estimate of $11.69.
What were Regeneron Pharmaceuticals’s (NASDAQ:REGN) revenues?
The Actual Revenue was $3.7B, which beat the estimate of $3.7B.
Browse earnings estimates, EPS, and revenue on all stocks.